These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 34917090)

  • 1. Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha.
    De Vlaminck K; Romão E; Puttemans J; Pombo Antunes AR; Kancheva D; Scheyltjens I; Van Ginderachter JA; Muyldermans S; Devoogdt N; Movahedi K; Raes G
    Front Immunol; 2021; 12():777524. PubMed ID: 34917090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis.
    Hu J; Xiao Q; Dong M; Guo D; Wu X; Wang B
    Front Immunol; 2020; 11():593219. PubMed ID: 33329583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
    Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
    Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.
    Yu GT; Bu LL; Huang CF; Zhang WF; Chen WJ; Gutkind JS; Kulkarni AB; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):42067-80. PubMed ID: 26573233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPα in adult T-cell leukemia/lymphoma.
    Yanagida E; Miyoshi H; Takeuchi M; Yoshida N; Nakashima K; Yamada K; Umeno T; Shimasaki Y; Furuta T; Seto M; Ohshima K
    Hematol Oncol; 2020 Dec; 38(5):680-688. PubMed ID: 32569413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRIM28 and β-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers.
    Jovčevska I; Zupanec N; Kočevar N; Cesselli D; Podergajs N; Stokin CL; Myers MP; Muyldermans S; Ghassabeh GH; Motaln H; Ruaro ME; Bourkoula E; Turnšek TL; Komel R
    PLoS One; 2014; 9(11):e113688. PubMed ID: 25419715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
    Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K
    Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo.
    Legrand N; Huntington ND; Nagasawa M; Bakker AQ; Schotte R; Strick-Marchand H; de Geus SJ; Pouw SM; Böhne M; Voordouw A; Weijer K; Di Santo JP; Spits H
    Proc Natl Acad Sci U S A; 2011 Aug; 108(32):13224-9. PubMed ID: 21788504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.
    Zhang X; Chen W; Fan J; Wang S; Xian Z; Luan J; Li Y; Wang Y; Nan Y; Luo M; Li S; Tian W; Ju D
    Carcinogenesis; 2018 May; 39(5):689-699. PubMed ID: 29538621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
    Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
    Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma.
    Hutter G; Theruvath J; Graef CM; Zhang M; Schoen MK; Manz EM; Bennett ML; Olson A; Azad TD; Sinha R; Chan C; Assad Kahn S; Gholamin S; Wilson C; Grant G; He J; Weissman IL; Mitra SS; Cheshier SH
    Proc Natl Acad Sci U S A; 2019 Jan; 116(3):997-1006. PubMed ID: 30602457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
    Ring NG; Herndler-Brandstetter D; Weiskopf K; Shan L; Volkmer JP; George BM; Lietzenmayer M; McKenna KM; Naik TJ; McCarty A; Zheng Y; Ring AM; Flavell RA; Weissman IL
    Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10578-E10585. PubMed ID: 29158380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts.
    Yabo YA; Moreno-Sanchez PM; Pires-Afonso Y; Kaoma T; Nosirov B; Scafidi A; Ermini L; Lipsa A; Oudin A; Kyriakis D; Grzyb K; Poovathingal SK; Poli A; Muller A; Toth R; Klink B; Berchem G; Berthold C; Hertel F; Mittelbronn M; Heiland DH; Skupin A; Nazarov PV; Niclou SP; Michelucci A; Golebiewska A
    Genome Med; 2024 Apr; 16(1):51. PubMed ID: 38566128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal-regulatory protein α from the NOD mouse binds human CD47 with an exceptionally high affinity-- implications for engraftment of human cells.
    Kwong LS; Brown MH; Barclay AN; Hatherley D
    Immunology; 2014 Sep; 143(1):61-7. PubMed ID: 24786312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and activation of signal regulatory protein alpha on astrocytomas.
    Chen TT; Brown EJ; Huang EJ; Seaman WE
    Cancer Res; 2004 Jan; 64(1):117-27. PubMed ID: 14729615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.